XNCR News and Press, Xencor Inc. From 05/26/21

-- Vir Biotechnology and GlaxoSmithKline's investigational SARS-CoV-2 antibody, engineered with the Xencor XmAb ® Fc technology, Xtend™, is authorized for treatment of mild-to-moderate COVID-19 in high-risk adults and pediatric patients -- -- Treatment with sot...

Xencor (XNCR) has entered into a technology license agreement with Bristol-Myers Squibb (BMY) for non-exclusive access to the company's Xtend Fc technology.The agreement looks to extend the half-life of a novel antibody combination therapy that is intended to neutralize the SARS-CoV-2 virus f...

The following slide deck was published by Xencor, Inc. in conjunction with this event. For further details see: Xencor (XNCR) Investor Presentation - Slideshow

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will participate in a ...

Xencor, Inc. (XNCR) Q1 2021 Results Conference Call May 05, 2021 04:30 PM ET Company Participants Charles Liles - Head of Investor Relations Bassil Dahiyat - President and Chief Executive Officer Allen Yang - Chief Medical Officer John Kuch - Chief Financial Officer John Desjarlais - Chief Sc...

Image source: The Motley Fool. Xencor Inc (NASDAQ: XNCR) Q1 2021 Earnings Call May 5, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Xencor Inc (XNCR) Q1 2021 Earnings Call Transcript

Xencor (XNCR): Q1 GAAP EPS of -$0.04 beats by $0.70.Revenue of $33.9M (+4.6% Y/Y) beats by $17.89M.Press Release For further details see: Xencor EPS beats by $0.70, beats on revenue

-- Management to Host Conference Call at 4:30 p.m. ET Today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results f...

Xencor (XNCR) announces that the first subject has been dosed in a randomized, double-blind, placebo-controlled Phase 1 clinical study of XmAb564, an engineered IL-2-Fc cytokine in development as a potential treatment for patients with autoimmune diseases.The study will evaluate the safety an...

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that the first subject has been dosed in a randomized, double-blind, placebo-controlled ...